



## ASX Release

31 August 2017

**ZELDA THERAPEUTICS LIMITED**  
**ACN 103 782 378**

Level 45  
108 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeldatherapeutics.com](mailto:enquiries@zeldatherapeutics.com)  
Web: [www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)

### Contacts

#### Corporate

Mr Harry Karelis  
Executive Chairman  
+61 413 056 328  
[hkarelis@zeldatherapeutics.com](mailto:hkarelis@zeldatherapeutics.com)

#### Investors

Dr Stewart Washer  
Executive Director  
+61 418 288 212  
[swasher@zeldatherapeutics.com](mailto:swasher@zeldatherapeutics.com)

### Directors

Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

### ASX Code:

ZLD

### Ordinary Shares:

754,841,934

### Options:

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -  
subject to vesting conditions)  
2,000,000 (\$0.04 - 6/2/2020)  
40,000,000 (\$0.03125-17/11/2021)

## CannPal Priority Share Offer Clarification Announcement

Further to the ASX announcement dated 29 August 2017 title 'Priority Share Offer for CannPal Animal Therapeutics Ltd IPO Shares', the Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** wishes to clarify the Priority Offer Record Date.

Under the CannPal Animal Therapeutics Ltd ('CannPal') Prospectus, 5,000,000 fully paid ordinary shares (Shares) at \$0.20 per Share have been allocated and made available to those ZLD shareholders registered on **4 September 2017** holding a minimum of 25,000 ZLD shares (Eligible ZLD Shareholders) collectively on a priority application basis.

**Tim Slate**  
**Company Secretary**

### **About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

The Company has secured certain rights to medicinal cannabis based formulations and treatment protocols developed over many years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile.